Current Clinical Guidelines for Preventing Chronic Kidney Disease

Primary Prevention Strategy

The KDIGO guidelines recommend a comprehensive framework for CKD prevention, emphasizing cardiovascular risk reduction through statin therapy, blood pressure control, diabetes management with SGLT2 inhibitors and GLP-1 receptor agonists, and lifestyle modifications including a Mediterranean-style diet 1
Cholesterol management is a key component of CKD prevention 2

For adults ≥50 years with eGFR <60 ml/min per 1.73 m², initiate a statin or statin/ezetimibe combination (Grade 1A recommendation) 1, 3
For adults ≥50 years with eGFR ≥60 ml/min per 1.73 m², use statin monotherapy (Grade 1B) 1, 2
For adults 18-49 years with CKD, initiate statins if they have coronary disease, diabetes, prior stroke, or >10% 10-year cardiovascular risk (Grade 2A) 1, 4
Choose statin regimens that maximize LDL cholesterol reduction for greatest benefit 3
Consider PCSK-9 inhibitors when indicated 3, 2
Use low-dose aspirin for secondary prevention in CKD patients with established ischemic cardiovascular disease (Grade 1C) 1, 2
Consider P2Y12 inhibitors if aspirin is not tolerated 2

SGLT2 inhibitors and GLP-1 receptor agonists represent breakthrough therapies that preserve kidney function while improving cardiovascular and metabolic outcomes 5, 6
SGLT2 inhibitors reduce intraglomerular pressure and should be continued even if eGFR falls below 20 ml/min per 1.73 m² unless kidney replacement therapy is initiated 6
Metformin remains a cornerstone of therapy when appropriate 5
Continue RAAS inhibitors unless creatinine rises >30% within 4 weeks of initiation or dose increase 6
Strict glycemic control prevents cardiovascular events in non-albuminuric individuals 7, 8
However, strict control shows no benefit in patients with baseline albuminuria >300 mg/g 7, 8

Adopt a plant-based Mediterranean-style diet in addition to pharmacologic therapy to reduce cardiovascular risk (KDIGO recommendation) 1, 3, 2
Limit foods rich in bioavailable potassium for patients with CKD G3-G5 who have hyperkalemia history 1, 3, 4
Limit alcohol to ≤1 drink/day for women and ≤2 drinks/day for men 9
Specifically limit alcohol intake to prevent gout in CKD patients 9, 10
Avoid alcohol entirely in patients with alcohol use disorder, symptomatic hyperuricemia, hypertriglyceridemia, uncontrolled hypertension, or liver disease 9

Treat symptomatic hyperuricemia with uric acid-lowering therapy (Grade 1C), but do NOT treat asymptomatic hyperuricemia to delay CKD progression (Grade 2D) 1, 3, 4, 2
Use xanthine oxidase inhibitors rather than uricosuric agents 1, 3, 10
Consider initiating therapy after the first gout episode, especially if serum uric acid >9 mg/dl 1, 3
For acute gout, use low-dose colchicine or glucocorticoids instead of NSAIDs 1, 3, 10
Limit alcohol, meats, and high-fructose corn syrup intake 1, 3, 2, 10

Monitor potassium levels regularly, being aware of measurement variability and factors affecting results 3, 4
Implement individualized dietary and pharmacologic interventions through consultation with a renal dietitian 1, 3, 4
Be aware of local availability of potassium exchange agents for non-emergent hyperkalemia 3, 4
Monitor for metabolic acidosis, which can worsen hyperuricemia and contribute to CKD progression 10
Consider pharmacological treatment when serum bicarbonate <18 mmol/l in adults 4
Ensure treatment doesn't cause bicarbonate to exceed normal limits or adversely affect BP or potassium 4

Avoid NSAIDs in CKD patients as they worsen renal function, increase hyperkalemia risk, and should never be used for pain management in this population 10, 6
Limit alcohol, meats, and high-fructose corn syrup intake 1, 3, 2, 10

Check serum electrolytes, particularly potassium 10
Assess acid-base status 10
Monitor blood pressure consistently 10
Refer promptly when patients have complications requiring specialist management 6

Do not rely solely on HbA1c for glycemic monitoring in advanced CKD, as it becomes unreliable due to reduced erythrocyte lifespan 10
Do not discontinue RAAS inhibitors prematurely unless creatinine rises >30%, symptomatic hypotension occurs, or uncontrolled hyperkalemia develops 6
Do not treat asymptomatic hyperuricemia to prevent CKD progression, as evidence does not support this practice 1, 10